SR 604
Alternative Names: SR-604Latest Information Update: 03 May 2024
At a glance
- Originator Equilibra Bioscience
- Class Antihaemorrhagics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Haemophilia A; Haemophilia B
Most Recent Events
- 15 Apr 2024 Phase-I clinical trials in Haemophilia A (Treatment experienced) in USA (SC) (NCT06349473)
- 15 Apr 2024 Phase-I clinical trials in Haemophilia B (Treatment experienced) in USA (SC) (NCT06349473)
- 08 Apr 2024 Equilibra Bioscience plans to initiate a phase I trial for Haemophilia A and Haemophilia B (Treatment experienced) (SC) (NCT06349473)